Pipeline news

• Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

  31 May 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced positive topline results from its Phase 2 clinical trial (“TYBEE”) evaluating suprachoroidal CLS-TA used with intravitreally administered EYLEA® (aflibercept) (“intravitreal Eylea”) in patients with diabetic macular edema (“DME”) over a 6-month evaluation period.

• Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration

  30 May 2018

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended  March 31, 2018 . In addition, the Company provided a clinical and business update. As of  March 31, 2018 , Syndax had  $113.2 million  in cash, cash equivalents and short-term investments.

• Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)

  17 May 2018

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated results from multiple cohorts of the ongoing Phase 2 ENCORE 601 trial of entinostat in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy. This data will be presented at the  American Society of Clinical Oncology  ( ASCO ) Annual Meeting being held  June 1-5, 2018  in  Chicago, Illinois .

• Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July

  17 May 2018

  

  Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today announced the last patient, last visit in its 200-patient acebilustat Phase 2b lung function preservation trial for the treatment of cystic fibrosis (CF). This trial has been carried out with the scientific and financial support of the CF Foundation.

• Epic Sciences Presents Detection and Characterization of Rare Peripheral CTC Immunogenicity and T-Cell Activation

  11 May 2018

  

  At the 2018 AACR annual meeting, Epic Sciences presented data from two studies demonstrating the company's "No Cell Left Behind" detection platform's capability to analyze potential markers of response to immuno-oncology (IO) agents, such as checkpoint inhibitors, vaccines, and CAR-T therapies. The first study presented single-cell sequencing of CTCs to detect DNA damage repair deficiencies (MSI or HRD) often associated with chromosomal instability or neo-antigen formation. The second study presented detection of rare immune cell populations, in this case T-cell activation (CD4/CD8/Ki67), from the same stable archived peripheral blood samples previously prepared for CTC analysis.

• Clearside Biomedical Announces First Quarter 2018 Financial Results and Provides Corporate Update

  09 May 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reported financial results for the quarter ended  March 31, 2018 , and provided an update on its development programs.

• Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update

  08 May 2018

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended  March 31, 2018 . In addition, the Company provided a clinical and business update. As of  March 31, 2018 , Syndax had  $113.2 million  in cash, cash equivalents and short-term investments.

• Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results

  02 May 2018

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the first quarter ended  March 31, 2018.

• Results from Positive Phase 2 Study of NovaDigm Therapeutics’ NDV-3A Vaccine Against Candida Published in Clinical Infectious Diseases

  25 April 2018

  

  NovaDigm Therapeutics, a company developing innovative immuno-therapeutics and preventative vaccines for fungal and bacterial infections, today announced the publication of data from a Phase 2a study of its NDV-3A vaccine program in the journal Clinical Infectious Diseases. The data demonstrate that a single dose of NDV-3A with alum adjuvant was safe, well-tolerated, immunogenic and efficacious, leading to reduced recurrences of vaginitis in patients with recurrent vulvovaginal candidiasis (RVVC). NDV-3A is the company’s lead development candidate to potentially treat or prevent diseases caused by fungal and bacterial pathogens, including antimicrobial-resistant strains.

• NovaDigm Therapeutics Announces Initiation of Phase 2a Clinical Trial of NDV-3A in Staphylococcus aureus

  19 April 2018

  

  NovaDigm Therapeutics, a company developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial infections, today announced the initiation of a Phase 2a study evaluating NDV-3A for the reduction of Staphylococcus aureus (S. aureus) colonization in a high-risk population of military trainees. The study is being conducted with the Uniformed Services University of the Health Sciences (USU) and is enrolling U.S. Army Infantry trainees at Fort Benning, GA. NDV-3A is the company’s lead development candidate to potentially treat antimicrobial resistant fungal and bacterial pathogens.